Author

Ulla Olsson‐Strömberg

Uppsala University

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cell type annotation· 2 Research Focus:differential expression· 2 Organism:human· 2 Approach:deep learning· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Assay:flow cytometry· 1 Assay:long-read sequencing· 1

Frequent Co-Authors

Bjørn Tore GjertseniD· 1 shared Chenyan WuiD· 1 shared Daryl Zhong Hao BoeyiD· 1 shared Dominik Georg Friedrich WolfiD· 1 shared Erin Craig· 1 shared Gunnar P. NilssoniD· 1 shared Henrik Hjorth‐HanseniD· 1 shared Jesper StentoftiD· 1 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Bjørn Tore GjertsenORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologyEuropean Journal Of HaematologyPeer-reviewedSep 17, 2026

Post-hoc long-read sequencing links leukemic mutation status to single-cell transcriptomes

Sofia Papavasileiou, Chenyan Wu, Daryl Zhong Hao Boey…·Joakim S. Dahlin

The paper develops a post-hoc method to link mutation status to single-cell transcriptomes using long-read sequencing, showing it can detect BCR::ABL1-positive cells in chronic myeloid leukemia.

DOI 10.1111/ejh.70322

humanscRNA-seq

𝕏 PostBluesky

Cancer BiologybioRxivPreprintNov 10, 2025

Deep single-cell immune and signaling profiles predict long term therapy response in chronic myeloid leukemia within hours

Stein‐Erik Gullaksen, Mathias Brevik, Øystein Sefland…·Bjørn Tore Gjertsen

The paper uses mass cytometry to analyze immune and signaling profiles in CML patients within hours of TKI treatment to predict 12-month treatment response.

DOI 10.1101/2025.11.10.687542

humanflow cytometry

𝕏 PostBluesky